[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353159-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353159-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dynamic-monitoring-of-antibody-drug-conjugates-targeting-trop2-or-her2-in-breast-cancer-using-circulating-tumor-cells-research-article","Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells - Research Article","","Antibody–drug conjugates (ADCs) use antibody targeting of tumor-enriched epitopes to internalize and deliver cytotoxic payloads, offering more selective therapy with improved toxicity profiles. ADCs against TROP2 or HER2 show activity in metastatic breast cancer, yet epitope levels in tumor biopsies have not consistently predicted clinical response. Serial quantitative imaging of circulating tumor cells (CTCs) in a prospective cohort of 35 patients shows strong within-patient heterogeneity of TROP2 and HER2. CTC epitope expression before therapy does not predict response depth, while low CTC burden or marked CTC reduction after three weeks predicts durable benefit, supporting payload sensitivity as a key driver.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dynamic-monitoring-of-antibody-drug-conjugates-targeting-trop2-or-her2-in-breast-cancer-using-circulating-tumor-cells-research-article/353159/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dynamic-monitoring-of-antibody-drug-conjugates-targeting-trop2-or-her2-in-breast-cancer-using-circulating-tumor-cells-research-article/353159.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the study evaluate TROP2 and HER2 in relation to ADC response?","Question",{"text":63,"@type":64},"The study performs serial quantitative imaging of circulating tumor cells in patients treated with ADCs targeting TROP2 or HER2, comparing epitope measurements from CTCs and paired tumor biopsies at the single-cell level.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Does baseline TROP2 or HER2 expression predict depth of clinical response?",{"text":68,"@type":64},"No. Measurement of TROP2 and HER2 on CTCs immediately prior to ADC therapy does not predict the depth of clinical response.",{"name":70,"@type":61,"acceptedAnswer":71},"What CTC-related factor predicts durable response in this cohort?",{"text":72,"@type":64},"Absence of CTCs or more than an 80% reduction in CTC numbers after three weeks (CTCLow) predicts durable response compared with CTC high cases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353159,1790644714,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nDynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells  \nAvanish Mishraa, b, 1, Rachel O. Abelmanc, 1, Quinn Cunneelya, b, 1, Victor Putaturoa, b, Akansha A. Deshpandea, b, Remy Bella, b, Elizabeth M. Seiderb, Katherine H. Xub, Mythreayi Shanb, Justin Kellyb, Shih-Bo Huangb,d, Olivia Rieurc, Justine Knapec, Kaustav A. Gopinathana, b, Kruthika Kikkeria, b, Jon F. Edda, b, John Walsha, b, Charles S. Daib,c, Leif W. Ellisenb,c , David T. Tingb,c , Linda Niemanb, Mehmet Tonera,e, Aditya Bardiac,2, Daniel A. Haberb,c,d,3 ,  \nand Shyamala Maheswaranb,3 Affiliations are included on p. 9.  \nContributed by Daniel A. Haber; received January 14, 2026; accepted May 11, 2026; reviewed by Guillermina Lozano and Kornelia Polyak  \nAntibody–drug conjugates (ADCs) target surface proteins on cancer cells, leading to internalization and delivery of a drug payload, thereby enhancing selectivity and minimizing toxicity. ADCs against TROP2 (Sacituzumab govitecan) or HER2 (T-DXd) have demonstrated efficacy in metastatic breast cancer, yet paradoxically, outside of HER2-amplified breast cancers, expression levels of these breast cancer-enriched epitopesin tumor biopsies have not been strongly correlated with clinical response. We undertook serial quantitative imaging of circulating tumor cells (CTCs) in a prospective cohort of 35 patients treated with either of these ADCs. At the single-cell level, expression of TROP2 and HER2 within individual patients is highly heterogeneous in both CTCsand paired tumor biopsies. Measurement of these epitopes on CTCs immediately prior toADC therapy does not predict depth of clinical response. However, absence of CTCsor >80% reduction in CTC numbers after three weeks of treatment (CTCLow) predicts durable response, compared with CTCHigh cases (TROP2: HR 5. 15, P = 0.012; HER2: HR 6.01, P \u003C 0.001) . Targeted epitopes are not commonly downregulatedon CTCs at the time of acquired clinical resistance, and switching between TROP2-and HER2-targeting ADCs sharing similar payloads infrequently leads to second-line response. Thus, while CTC burden is correlated with response to these ADCs, the level of TROP2 or HER2 expression is poorly predictive. These findings point to sensitivity to the drug payload as a potential driver of clinical response to currently approved ADCsin breast cancer.  \nantibody-drug-conjugate | breast cancer | circulating tumor cells | TROP2 | HER2  \nAntibody–drug conjugates (ADCs) combine an antibody specifically targeting a tumor cell-enriched epitope with a cytotoxic payload, thereby providing the potential to deploy more selective chemotherapy with a favorable therapeutic window and toxicity profile ( 1) . This delivery of payload to cells containing tumor-associated antigens allows the use of drugs substantially more toxic than traditional chemotherapy (2) . ADCs were first deployed in breast cancer for the treatment of metastatic breast cancer (MBC) with HER2 gene amplification (HER2+) (3) . Subsequently, ADCs have been FDA-approved for advanced MBCs lacking HER2 gene amplification, including two that target another cell surface epitope, TROP2 [sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd)], and one targeting HER2 [trastuzumab deruxtecan (T-DXd)](4–7) . The promising first-line application of ADCs in combination with either immune checkpoint blockade (ASCENT-04 trial: SG + pembrolizumab vs. chemotherapy + pembrolizumab for metastatic TNBC) (8) or with antibody disrupting HER2 dimerization (DESTINY-Breast09 trial: T-DXd + pertuzumab vs. paclitaxel + trastuzumab + pertuzumab for HER2+ breast cancer) (9, 10) is poised to revolutionize the treatment of MBC, potentially replacing traditional chemotherapy as first-line regimens. In addition to the treatment of metastatic cancer, ADCs are being tested in the potentially curative setting of adjuvant therapy for localized br","cbCaidPuKX7IntF8","https://ap.wps.com/l/cbCaidPuKX7IntF8","pdf",1928707,"English","# Significance\n## Abstract overview\n## Key findings","[{\"question\":\"How does the study evaluate TROP2 and HER2 in relation to ADC response?\",\"answer\":\"The study performs serial quantitative imaging of circulating tumor cells in patients treated with ADCs targeting TROP2 or HER2, comparing epitope measurements from CTCs and paired tumor biopsies at the single-cell level.\"},{\"question\":\"Does baseline TROP2 or HER2 expression predict depth of clinical response?\",\"answer\":\"No. Measurement of TROP2 and HER2 on CTCs immediately prior to ADC therapy does not predict the depth of clinical response.\"},{\"question\":\"What CTC-related factor predicts durable response in this cohort?\",\"answer\":\"Absence of CTCs or more than an 80% reduction in CTC numbers after three weeks (CTCLow) predicts durable response compared with CTC high cases.\"}]","Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells - Research Article | PDF",1790103340,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfdcde3a53ade483fb3de08492c4b02d.webp",983,1316,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e9fe82b3d48149ea60decc92b7ddb09.webp",982,1315,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/823ed4f60df1ef0aebb480b266234314.webp",981,1313,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59cf75200d0981743dd65fabf65e865e.webp",980,1312]